Protox has taken the first step to commercialize its self-developed Botox (botulinum toxin).

Protox announced on the 25th that it will start GLP non-clinical trials of its new botulinum toxin A preparation (tentatively named Protoxin).

The production of non-clinical trial products was completed and delivered to Biotoxtech, a GLP (non-clinical practice practice) organization. The goal is to end the non-clinical trial in the second half of this year and apply for approval of the investigational plan (IND).

An official from Protox said, “The GMP plant under construction in the Hyangnam Pharmaceutical Complex is scheduled to be completed next month,” adding, “We are continuously adding manpower to improve the perfection of Protoxin and commercialize it in earnest.”

Protox is a subsidiary of KOSDAQ-listed DSK (68.76% stake).

[Money Today Broadcasting MTN = Reporter Lee Dae-ho (robin@mtn.co.kr)]